Mustang Bio Q2 net loss widens 41% to $1.07 million
MBIO•Quarterly results
Mustang Bio posted a GAAP net loss of $1.07 million for the quarter ended June 30, 2026, widening 41%.
Operating loss widened 32% to $1.17 million as total operating expenses rose 32% to $1.17 million.
R&D expense more than doubled to $224,000 while G&A increased 20% to $946,000.
Cash position and program update
Cash and cash equivalents totaled $15.2 million as of June 30, 2026; accumulated deficit stood at $400.7 million.
Mustang Bio continued planning an MB-109 investigator-sponsored trial at City of Hope, targeting a potential fourth-quarter 2026 initiation.
